

Neuro aktuell

Ausgabe 1-2021

Literatur

Schwerpunkt: Kopfschmerz

Titel: Prävention der Migräne-Chronifizierung (S. 7–11)

Autor: M. Keidel

Literatur:

1. Linde M et al. Time trends in the prevalence of headache disorders. The Nord-Trøndelag Health Studies (HUNT 2 and HUNT 3). *Cephalalgia* 2011; 31(5): 585–596
2. Lipton RB et al. Migraine in the United States: epidemiology and patterns of health care use. *Neurology*. 2002; 58(6): 885–894
3. Keidel M (Hrsg.) Migräne. Ursachen, Formen, Therapie. C.H.Beck Verlag, München, 2007
4. Burch RC et al. Migraine: Epidemiology, Burden, and Comorbidity. *Neurol Clin* 2019; 37(4): 631–649
5. Lipton RB et al. Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. *Neurology* 2015; 84(7): 688–695
6. May A & Schulte LH. Chronic migraine: risk factors, mechanisms and treatment. *Nat Rev Neurol* 2016; 12(8): 455–464
7. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). *Cephalalgia* 2013; 33(9): 629–808
8. Teixeira AL et al. Psychiatric comorbidities of chronic migraine in community and tertiary care clinic samples. *J Headache Pain* 2012; 13(7): 551–555
9. Minen MT et al. Migraine and its psychiatric comorbidities. *J Neurol Neurosurg Psychiatry* 2016; 87(7): 741–749
10. Bigal ME & Lipton RB. Modifiable risk factors for migraine progression. *Headache* 2006 Oct; 46(9): 1334–1343
11. Tietjen GE et al. Childhood maltreatment and migraine (part III). Association with comorbid pain conditions. *Headache* 2010; 50(1): 42–51
12. Tietjen GE et al. Childhood maltreatment and migraine (part II). Emotional abuse as a risk factor for headache chronification. *Headache* 2010; 50(1): 32–41
13. Oedegaard KJ et al. Migraine with and without aura: association with depression and anxiety disorder in a population-based study. The HUNT Study. *Cephalalgia* 2006; 26(1): 1–6
14. Breslau N et al. Headache and major depression: is the association specific to migraine? *Neurology* 2000; 54(2): 308–313
15. Lateef T et al. Headaches and sleep problems among adults in the United States: findings from the National Comorbidity Survey-Replication study. *Cephalalgia* 2011; 31(6): 648–653
16. Buse DC et al. Sleep Disorders Among People With Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. *Headache* 2019; 59(1): 32–45
17. Hepp Z et al. Adherence to oral migraine-preventive medications among patients with chronic migraine. *Cephalalgia* 2015; 35(6): 478–488
18. Diener HC et al. Prophylaxe der Migräne mit monoklonalen Antikörpern gegen CGRP oder den CGRP-Rezeptor, Ergänzung der S1-Leitlinie Therapie der Migräneattacke und Prophylaxe

- der Migräne, 2019. In: Deutsche Gesellschaft für Neurologie, Hrsg. Leitlinien für Diagnostik und Therapie in der Neurologie. (www.dgn.org/leitlinien). Zugegriffen: 16.11.2020
19. Diener HC et al. Therapie der Migräneattacke und Prophylaxe der Migräne, S1-Leitlinie, 2018. In: Deutsche Gesellschaft für Neurologie, Hrsg. Leitlinien für Diagnostik und Therapie in der Neurologie. (www.dgn.org/leitlinien). Zugegriffen: 16.11.2020
 20. Keidel M. Multimodale Schmerztherapie bei Kopfschmerzen. *Jatros Neurologie & Psychiatrie* 2019; 3
 21. Keidel M, Hrsg. Kopfschmerz-Management in der Praxis. Stuttgart, New York: Thieme; 2006
-

Schwerpunkt: Schlaganfall

Titel: Prähospitaler Triage: Wahl des primären Zielkrankenhauses bei Schlaganfall mit unklarem Gefäßstatus (S. 12–21)

Autoren: L. Schlemm, M. Endres

Literatur:

1. Feigin VL et al. Global Burden of Stroke. *Circ Res.* 2017; 120: 439–448
2. Powers WJ et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke* 2019; 50: e344–e418
3. Wollenweber FA et al. Functional Outcome Following Stroke Thrombectomy in Clinical Practice. *Stroke* 2019; 50: 2500–2506
4. Smith EE et al. Accuracy of Prediction Instruments for Diagnosing Large Vessel Occlusion in Individuals With Suspected Stroke: A Systematic Review for the 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke. *Stroke* 2018; 49: e111–e122
5. Tebb MS et al. Stroke vision, aphasia, neglect (VAN) assessment—a novel emergent large vessel occlusion screening tool: pilot study and comparison with current clinical severity indices. *J Neurointerv Surg* 2017; 9: 122–126
6. Katz BS et al. Design and validation of a prehospital scale to predict stroke severity: Cincinnati Prehospital Stroke Severity Scale. *Stroke* 2015; 46: 1508–1512
7. Nazliel B et al. A brief prehospital stroke severity scale identifies ischemic stroke patients harboring persisting large arterial occlusions. *Stroke* 2008; 39: 2264–2267
8. Perez de la Ossa N et al. Design and validation of a prehospital stroke scale to predict large arterial occlusion: the rapid arterial occlusion evaluation scale. *Stroke* 2014; 45: 87–91
9. Singer OC et al. A simple 3-item stroke scale: comparison with the National Institutes of Health Stroke Scale and prediction of middle cerebral artery occlusion. *Stroke* 2005; 36: 773–776
10. Pride GL et al. Prehospital care delivery and triage of stroke with emergent large vessel occlusion (ELVO): report of the Standards and Guidelines Committee of the Society of Neurointerventional Surgery. *J Neurointerv Surg* 2017; 9: 802–812
11. Hastrup S et al. Response by Hastrup et al to Letter Regarding Article, "Prehospital Acute Stroke Severity Scale to Predict Large Artery Occlusion: Design and Comparison With Other Scales". *Stroke* 2016; 47: e243
12. Schlemm L et al. Comparative Evaluation of 10 Prehospital Triage Strategy Paradigms for Patients With Suspected Acute Ischemic Stroke. *J Am Heart Assoc* 2019; 8: e012665

13. Abilleira S et al. Transfer to the Local Stroke Center versus Direct Transfer to Endovascular Center of Acute Stroke Patients with Suspected Large Vessel Occlusion in the Catalan Territory (RACECAT): Study protocol of a cluster randomized within a cohort trial. *Int J Stroke* 2019; 14: 734–744
 14. Behrndtz A et al. TRIAGE-STROKE: Treatment strategy In Acute larGE vessel occlusion: Prioritize IV or endovascular treatment-A randomized trial. *Int J Stroke* 2020; 15: 103–108
 15. Froehler MT et al. Interhospital Transfer Before Thrombectomy Is Associated With Delayed Treatment and Worse Outcome in the STRATIS Registry (Systematic Evaluation of Patients Treated With Neurothrombectomy Devices for Acute Ischemic Stroke). *Circulation* 2017; 136: 2311–2321
 16. Holodinsky JK et al. Mathematical Modeling for Decision-Making in the Field for Acute Stroke Patients With Suspected Large Vessel Occlusion. *Stroke* 2018: STROKEAHA118021381
 17. Holodinsky JK et al. Modeling Stroke Patient Transport for All Patients With Suspected Large-Vessel Occlusion. *JAMA Neurol* 2018; 75: 1477–1486
 18. Venema E et al. Personalized Prehospital Triage in Acute Ischemic Stroke. *Stroke* 2019; 50: 313–320
 19. Schlemm L et al. Bypassing the Closest Stroke Center for Thrombectomy Candidates: What Additional Delay to Thrombolysis Is Acceptable? *Stroke* 2020; 51: 867–875
 20. Schlemm L & Schlemm E. Clinical benefit of improved Prehospital stroke scales to detect stroke patients with large vessel occlusions: results from a conditional probabilistic model. *BMC Neurol* 2018; 18: 16
 21. Kobayashi A et al. European Academy of Neurology and European Stroke Organization consensus statement and practical guidance for pre-hospital management of stroke. *Eur J Neurol* 2018; 25: 425–433
 22. Turc G et al. European Stroke Organisation (ESO) - European Society for Minimally Invasive Neurological Therapy (ESMINT) Guidelines on Mechanical Thrombectomy in Acute Ischemic Stroke. *J Neurointerv Surg* 2019
 23. The American Heart Association and American Stroke Association. Mission: Lifeline® Stroke Severity-Based Stroke Triage Algorithm for EMS 2020 [cited 2020 12.09.2020]. (<https://www.heart.org/en/professional/quality-improvement/mission-lifeline/mission-lifeline-stroke>). Zugegriffen: 01.02.2021
 24. Deutsche Schlaganfallgesellschaft. Persönliche Kommunikation vom 21.09.2020
 25. Xu Y et al. Decision Analysis Model for Prehospital Triage of Patients With Acute Stroke. *Stroke* 2019; 50: 970–977
-

Schwerpunkt: Restless-Legs-Syndrom

Titel: Translation von konsensbasierten Beschlüssen zur Eisentherapie des Restless-Legs-Syndrom – schnell genug in die tägliche Praxis? (S. 29–36)

Autor: H.-K. Goischke

Erratum:

- S. 29: Auf dieser Seite muss es im letzten Absatz rechts unten lauten:
„Eisen ist ein wesentlicher Kofaktor für Tyrosinhydroxylase bei der enzymatischen Umwandlung von *L-Tyrosin* zu L-Dopa, dem Hauptvorläufer für Dopamin [11].“

Literatur:

1. Allen RP et al. Restless legs syndrome prevalence and impact: REST general population study. *Arch Intern Med* 2005; 165: 1286–1292
2. Oertel WH et al. Restless-Legs-Syndrom. *Dtsch Arztlbl* 2000; 97: 2932–2940
3. Breymann C et al. Behandlung von Eisenmangel bei Frauen. *Geburtshilfe Frauenheilk* 2013; 73(3): 250–261
4. Allen RP et al. MRI measurement of brain iron in patients with restless legs syndrome. *Neurology* 2001; 56: 263–265
5. Allen RP et al. Iron-deficiency and dopaminergic treatment effects on RLS-Like behaviors of animal model with the brain iron deficiency pattern of the restless legs syndrome. *Sleep Med* 2020; 71: 141–148
6. Rizzo G et al. Low brain iron content in idiopathic restless legs syndrome patients detected by phase imaging. *Mov Disord* 2013; 28: 1886–1890
7. Earley CJ et al. MRI-determined regional brain iron concentrations in early- and late-onset restless legs syndrome. *Sleep Med* 2006; 7: 458–461
8. Godau J et al. Multiregional brain iron deficiency in restless legs syndrome. *Mov Disord* 2008; 23: 1184–1187
9. Connor JR et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. *Neurology* 2003; 61: 304–309
10. Connor JR et al. Profile of altered brain iron acquisition in restless legs syndrome. *Brain*. 2011; 134(4): 959–968
11. Koo BB et al. Restless legs syndrome: Current concepts about disease pathophysiology. *Tremor Other Hyperkinetic Mov* 2016; 6: 401
12. Walter U & Behnke St. Transcranial Sonography of Brain Parenchyma: Established Applications in Adults. *Klin Neurophysiol* 2019; 50(02): 73–82
13. Schmidauer CH et al. Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndrome. *Annals of Neurology* 2005; 58: 630–634
14. Stockner et al. Transkranielle Sonographie des Hirnparenchyms. *Ultraschall in Med* 2006; 27: V254
15. Godau J, Sojer M. Transcranial sonography in restless legs syndrome. *Int Rev Neurobiol* 2010; 90: 99–215
16. Kwon DY et al. Transcranial brain sonography in Parkinson's disease with restless legs syndrome. *Mov Disord* 2010; 25(10): 1373–1378
17. Didato G et al. Restless Legs Syndrome across the Lifespan: Symptoms, Pathophysiology, Management and Daily Life Impact of the Different Patterns of Disease Presentation. *Int J Environ Res Public Health* 2020; 17(10): 3658
18. Allen RP et al. Evidence-based ad consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report. *Sleep Med* 2018; 41: 27–44
19. Earley CJ et al. Insight into the pathophysiology of restless legs syndrome. *Journal of Neuroscience Research* 2000; 62: 623–628
20. Early CJ et al. Altered Brain iron homeostasis and dopaminergic function in Restless Legs Syndrome (Willis–Ekbom Disease). *Sleep Med* 2014; 15(11):1288–1301
21. Trenkwalder C et al. Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: a randomized trial. *Mov Disord* 2017; 32: 1478–1482
22. Trotti M, Becker LA. Iron for the treatment of restless legs syndrome. *Cochrane Database of Systematic Reviews* 2019; 146–18523

23. Allen RP et al. Clinical efficiency and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial. *Sleep Med* 2011; 12: 906–13
24. Early CJ et al. The treatment of restless legs syndrome with intravenous iron dextran. *Sleep Med* 2004; 5: 231–35
25. Avni T et al. Iron supplementation for restless legs syndrome- A systematic review and meta-analysis. *Eur J Intern Med* 2019; 63: 34–41
26. Bartl M et al. Restless-legs Syndrom: ein Update. *Nervenarzt* 2020; 91(10): 955–966
27. Wijemanne S, Jankovic J. Restless legs syndrome: clinical presentation diagnosis and treatment. *Sleep Med* 2015; 16(6): 678–90
28. Koo BB et al. Restless Legs Syndrome & Depression: Effect Mediation by Disturbed Sleep and Periodic Limb Movements. *Am J Geriatr Psychiatry* 2016; 24(11): 1105–1116
29. Ferreira A et al. Multilevel Impacts of Iron in the Brain: The Cross Talk between Neurophysiological Mechanisms, Cognition, and Social Behavior. *Pharmaceuticals* 2019; 12(3): 120
30. Lee HS et al. Psychiatric disorders risk in patients with iron deficiency anemia and association with iron supplementation medications: a nationwide database analysis. *MMC Psychiatry* 2020; 20: 16
31. Gupta R et al. Restless legs syndrome and pregnancy: prevalence possible pathophysiological mechanisms and treatment. *Acta Neurol Scand* 2016; 133(5): 320–329
32. Vadasz D et al. Intravenous iron sucrose for restless legs syndrome in pregnant women with low serum ferritin. *Sleep Med*. 2013; 14: 1214–16
33. Picchietti DL et al. Consensus clinical practice guidelines for the diagnosis and treatment of restless legs syndrome/Willis-Ekbom disease during pregnancy and lactation. *Sleep Medic Rev* 2015; 22: 64–77
34. Neyal A et al. A prospective study of Willis-Ekbom disease/restless legs syndrome during and after pregnancy. *Sleep Med* 2015; 16(9): 1036–1040
35. Schreckenbach T, Busch R. Zoom: Restless legs syndrom (Willis-Ekbom Disease): Die „ruhelosen Beine“ effektiv behandeln. *DGNeurologie* 2019; 2(5): 336–337
36. Hidese S et al. Association between iron-deficiency anemia and depression. *Psychiatry Clin Neurosci* 2018; 72(7): 513–21
37. Mills NT et al. Investigating the relationship between iron and depression. *Journal of Psychiatric Research*, 2017; 94: 148–155
38. Schneider J et al. Open-label study of the efficacy and safety of intravenous ferric carboxymaltose in pregnant women with restless legs syndrome. *Sleep Med* 2015; 16(11): 1342–1347
39. Oran M et al. Possible association between vitamin D deficiency and restless legs syndrome. *Neuropsychiatr Dis Treat* 2014; 10: 953–8
40. Wali S et al. The effect of vitamin D supplements on the severity of restless legs syndrome. *Sleep Breath* 2015; 19: 579–83
41. Cass WA et al. Calcitriol promotes augmented dopamine release in the lesioned striatum of 6-hydroxydopamine treated rats. *Neurochem Res* 2014; 39: 1467–76
42. Balaban H et al. Serum 25-hydroxyvitamin D levels in restless legs syndrome patients. *Sleep Med* 2012; 13: 953–7
43. Malczewska-Lenczowska J et al. The Association between Iron and Vitamin D Status in Female Elite Athletes, *Nutrients* 2018; 10(2): 167
44. Lee JA et al. Low Vitamin D Levels Are Associated with Both Iron Deficiency and Anemia in Children and Adolescents. *Pediatric Hematology and Oncology* 2015; 32(2): 99–108

45. Gozzelino R et al. Iron as Therapeuticum Target in Human disease. *Pharmaceuticals* 2019; 12: 178
46. Mumford SL et al. Association of preconception serum 25-Hydroxyvitamin D concentrations with livebirth and pregnancy loss: a prospective cohort study. *Lancet Diabetes Endocrinol* 2018; 6: 725–732
47. Bi WG et al. Association Between Vitamin D Supplementation During Pregnancy and Offspring Growth, Morbidity, and Mortality: A Systematic Review and Meta-analysis. *JAMA Pediatr* 2018; 172: 653–645
48. Wagner CL, Hollis BW. The Implication of Vitamin D Status During Pregnancy on Mother and her Developing Child. *Front Endocrinol* 2018; 9: 500
49. Yates N et al. Vitamin D deficiency and impaired placental function: potential regulation by glucocorticoids? *Reproduction* 2017; 153: 163–171
50. Dobson R et al. Vitamin D supplementation. *Pract Neurol* 2017; 18(1): 35–42
51. Oliveira C et al. Associations Between Vitamin D Levels and Depressive Symptoms in Later Life: Evidence From the English Longitudinal Study of Ageing (ELSA). *J Gerontol A Biol Sci Med Sci* 2018; 73(10): 1377–1382
52. Penckofer S et al. Vitamin D and Depression: Where is all the Sunshine? *Issues Ment Health Nurs* 2010; 31(6): 385–393
53. Anglin RES et al. Vitamin D deficiency and depression in adults: systematic review and meta-analysis. *The British Journal of Psychiatry* 2013; 202(2): 100–107
54. Hansen JP et al. Vitamin D3 supplementation and treatment outcomes in patients with depression (D3-vit-dep). *BMC Res Notes* 2019; 12: 203
55. Gowda U et al. Vitamin D supplementation to reduce depression in adults: meta-analysis of randomized controlled trials. *Nutrition* 2015; 31(3): 421–429
56. Kotb MA et al. Effect of vitamin D replacement on depression in multiple sclerosis patients. *MSARD* 2019;29:111-117
57. Osimo EF et al. Inflammatory markers in depression: A meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls. *Brain Behav Immun* 2020 ;87: 901–909
58. Calton EK et al. The Impact of Vitamin D Levels on Inflammatory Status: A Systematic Review of Immune Cell Studies. *PLoS* 2015;10(11): e0141770
59. Winkelmann J et al. Treatment of Restless Legs Syndrome: Evidence-Based Review and Implications for Clinical Practice (Revised 2017) *Mov Disord* 2018; 33(7): 1077–1091
60. Cho YW et al. Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome. *Sleep Med* 2016; 25: 16–23
61. Bregman DB et al. Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia. *Am J Hematol* 2013; 88(2): 97–101
62. Moretti D et al. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. *Blood* 2015; 126(17): 1981–198
63. Weinstock LB, Walters AS. Restless legs syndrome is associated with irritable bowel syndrome and small intestinal bacterial overgrowth. *Sleep Me* 2011; 12(6): 610–3
64. Yun CH H et al. Association between irritable bowel syndrome and restless legs syndrome in the general population. *J Sleep Res* 2012;21(5)
65. Gallan L. The gut microbiome and the brain. *J Med Food* 2014; 17(12): 1261–1272
66. Gutschow P et al. Clinical Immunoassay for Human Hepcidin Predicts Iron Deficiency in First-Time Blood Donors. *JALM* 2020; 5(5): 943–953
67. Chenini S et al. Hepcidin and ferritin levels in restless legs syndrome: a case-control study. *Scientific Reports* 2020; 10: 11914

68. Smith EM et al. High-dose Vitamin D3 reduces circulating hepcidin concentrations: a pilot, randomized, double-blind, placebo-controlled trial in healthy adults. *Clin Nutr* 2017; 36(4): 980–985
69. Park HR et al. Patient characteristics predicting responses to intravenous ferric carboxymaltose treatment of restless legs syndrome. *Sleep Med* 2020; 75: 81–87
70. Macher S et al. The Effect of Parenteral or Oral Iron Supplementation on Fatigue, Sleep, Quality of Life and Restless Legs Syndrome in Iron-Deficient Blood Donors: A Secondary Analysis of the Iron Wo Man. RCT. *Nutrients* 2020; 12(5): 1313
71. Trenkwalder C et al. Augmentation in restless legs syndrome is associated with low ferritin. *Sleep Med* 2008; 9(5): 572–574
72. Garcia-Malo C et al. Quantitative transcranial sonography of the substantia nigra as a predictor of therapeutic response to intravenous iron therapy in restless legs syndrome. *Sleep Med* 2020; 66: 123–129
73. Garcia-Malo C et al. Iron replacement therapy in Restless legs Syndrome. *Curr Treat Options Neurol*. Publ. online 17 March 2020
74. Saglam G et al. The Relationship Between vitamin D Deficiency and Restless Legs Syndrome in Pregnancy. *J Turk Sleep Med* 2020; 2: 44–48
75. Xu Y et al. The importance of vitamin D metabolism as a potential prophylactic, immunoregulatory and neuroprotective treatment for COVID19. *Transl Med* 2020; 18: 322
76. Fiorino S et al. The rationale for a multi-step therapeutic approach based on antivirals, drugs and nutrients with immunomodulatory activity in patients with coronavirus-SARS2-induced disease of different severities. *Br J Nutr* 2020; online 24 July 2020
77. Grant WB et al. Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths. *Nutr* 2020;12(4):988
78. Garcia-Malo C et al. Low risk of iron overload or anaphylaxis during treatment of restless legs syndrome with intravenous iron: a consecutive case series in a regular clinical setting. *Sleep Med* 2020; 74: 48–55